Given the results of the recently published GETUG 16 randomized trial, should all men undergoing salvage prostate radiotherapy receive concurrent hormone therapy?

In this trial, 6 months of concurrent LHRH agonist therapy improved 5-year progression-free survival from 62% to 80%, with similar benefit in low-risk (Gleason <8, PSADT >6 months, surgical margins-positive and SV invasion-negative) and high-risk (all other) patients. There was no difference in quality of life, G3+ acute toxicity or any grade late toxicity. Is any subgroup of men favorable enough to be treated with RT alone? Should at least short-term ADT be recommended, since it does not significantly affect QOL or toxicity (except G1-2 acute)?